Physician profile
David Poon
NPI 1376861864
$3,795.64
in general payments reported to CMS, 2019-2025
21 companies · $874 in 2025
The $874 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $167 · 2021: $187 · 2022: $474 · 2023: $687 · 2024: $706 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,266.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $943.15 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $649.25 | 2019-2025 | Vabysmo |
| Glaukos Corporation | $297.65 | 2019-2025 | Idosetr |
| Bausch & Lomb Americas INC. | $275.00 | 2024-2025 | Envista Mx60 Iol, Xiidra, Miebo |
| Aerie Pharmaceuticals, INC. | $237.63 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $205.16 | 2022-2025 | Syfovre |
| Abbvie INC. | $201.17 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $123.83 | 2025 | Xdemvy |
| Recordati_rare_diseases_inc. | $122.19 | 2024 | Cystadrops |
| Sun Pharmaceutical Industries INC. | $122.11 | 2023 | Cequa |
| Kala Pharmaceuticals, INC. | $119.32 | 2019 | |
| Asd Specialty Healthcare, LLC | $104.50 | 2019 | |
| Allergan, INC. | $78.77 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $68.80 | 2019 | |
| Coherus Oncology, INC. | $67.12 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $61.31 | 2021-2022 | |
| Sandoz INC. | $32.51 | 2024 | Cimerli |
| Alimera Sciences, INC. | $31.65 | 2022 | |
| Astellas Pharma US INC | $20.97 | 2025 | Izervay |
| Biogen, INC. | $16.79 | 2023 | |
| Novartis Pharmaceuticals Corporation | $16.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Poon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.